Physician profile
Daniel J Beers
NPI 1578625810
$3,690.16
in general payments reported to CMS, 2019-2025
23 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $570 · 2021: $696 · 2022: $635 · 2023: $263 · 2024: $423 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.74 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $798.63 | 2020-2025 | |
| Eyevance Pharmaceuticals LLC | $504.38 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $362.85 | 2019-2025 | |
| Oyster Point Pharma, INC. | $304.51 | 2022-2025 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $210.94 | 2019-2022 | |
| Alcon Vision LLC | $174.30 | 2019-2025 | Clareon, Wavelight Ex500 Excimer Laser |
| Johnson & Johnson Surgical Vision, INC. | $163.42 | 2021-2024 | |
| Aerie Pharmaceuticals, INC. | $151.28 | 2019-2021 | |
| Dompe US, INC. | $144.24 | 2019-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $142.70 | 2019-2022 | |
| Abbvie INC. | $140.55 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $119.77 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Glaukos Corporation | $105.01 | 2022-2023 | Photrexa Cross-Linking Kit, Istent Infinite Trabecular Micro-Bypass System Model Is3, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Tarsus Pharmaceuticals, INC. | $70.83 | 2024-2025 | Xdemvy |
| Rxsight INC | $60.67 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $51.78 | 2024-2025 | Iheezo, Ilevro |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $43.80 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $38.35 | 2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $23.45 | 2021 | |
| Sight Sciences, INC. | $22.68 | 2022 | |
| Ivantis, INC | $22.52 | 2020 | |
| Horizon Therapeutics Plc | $20.81 | 2023 | Tepezza |
| Iridex Corporation | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Beers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.